On November 2, the official website of the Sanming Purchasing Alliance released the "Letter on the Eighth Centralized Banded Purchasing of Medical Consumables by the Sanming Purchasing Alliance", which mentioned that the Hebei Provincial Medical Insurance Bureau will be entrusted to take the lead in organizing and carrying out the eighth centralized banded purchasing of medical consumables, which involves 20 kinds of medical consumables, including rigid gas permeable contact lenses for corneal reshaping (popularly known as OK lenses), artificial bones, cardiac fixators, cranial stents and so on. These include rigid gas permeable contact lenses for corneal reshaping (commonly known as "OK lenses"), artificial bone, cardiac immobilizers, intracranial stents, and so on. The alliance cities need to report the results to the Sanming Purchasing Alliance by November 8th.
According to the official website, members of the Sanming alliance now cover 30 prefectural-level cities in 16 provinces across the country and four national healthcare reform demonstration counties, covering a regional population of more than 160 million people. Sanming City Medical Protection Bureau relevant person in charge of the "Securities Daily" reporter said in an interview, the collection is mainly to follow up on the Hebei Provincial Bureau of Medical Insurance led by the organization to carry out the eighth centralized banded procurement of medical consumables. Previously, the Sanming Purchasing Alliance has carried out a number of medical consumables procurement, and with the accession of the Sanming Purchasing Alliance, Hebei Province, 20 kinds of medical consumables procurement will have a greater and wider impact.
An investment agency's investment director said to the "Securities Daily" reporter, "the inclusion of 20 kinds of medical supplies in addition to the OK mirror, basically are medical insurance scope of supplies, mainly concentrated in orthopedics, cardiovascular interventional surgery and other areas of the field, the clinical use of a larger amount of consumables, the value of a relatively high. The main reason for the inclusion of OK lenses in the collection and procurement, on the other hand, is that its unit price of about 10,000 yuan is too high, and with the development of the eye needs to be re-purchased, which greatly aggravates the pressure on the consumer's health care expenditures."
Hainan Boao Medical Technology Co., Ltd. general manager Deng Zhidong told the "Securities Daily" reporter, "This collection of selected products, rich in categories. In addition, this has been the eighth round of Sanming Purchasing Alliance medical consumables collection, visible health insurance collection will be further accelerated and expanded, the national pharmaceutical collection gradually entered the normalization and institutionalization stage. This will be conducive to the promotion of the 'three medical linkage', and promote the formation of a new pattern of fair competition, quality assurance, innovation-driven market development."
"The core of collective purchasing is to exchange volume for price, and most of the recent collective purchasing of consumables has focused on low- and medium-value consumables, or consumables with an already high domestic production rate. After the full implementation of medical consumables band purchasing, a small number of winning enterprises will *** enjoy 60% to 70% of the national market, and ultimately form a pattern in which the head enterprises with strong innovation ability occupy a larger market share, and the consumables enterprises with poorer innovation ability will be gradually eliminated, and the concentration of the industry will gradually increase." Qin Liang, senior investment consultant of East High-Tech, said in an interview with the Securities Daily.
Qin Liang said, "medical consumables collection is similar to the previous drug collection, the purpose is to encourage enterprises to improve R & D, innovation, high-end devices, consumables in the field of domestic independent. For medical device manufacturers, in the long run is to promote the process of 'qualitative change', the need to continue to increase product research and development efforts, innovation, medical value to seek more incremental. And for innovative high-value consumables companies, product development to take more account of the advantages and disadvantages of competing products, to make both innovative and differentiated products."
"The existing collection and procurement policy from the past to suppress the price change to promote the standardized development of the industry, suppress the intermediary price difference, leaving a certain profit margin to enterprises and innovation and R & D costs of the mature interests of the control mechanism." The above investment director told reporters. "This move is especially favorable to small and medium-sized innovative medical device companies, these companies before the biggest problem is that there is a good product, no good channels, and thus can not form a good performance, but in the context of the collection and procurement, the channel and sales problems will be solved, the enterprise only need to do a good job of the product, and then control the related costs and product prices."
Deng Zhidong said, "under the trend of normalization of collective procurement, pharmaceutical companies want long-term development, need to more optimize the enterprise development strategy, clear development goals and business model, find the market positioning and target customer groups, to provide a higher level, more diversified quality services, to build the drug R & D ecosystem, the use of advanced technology to empower, improve quality, reduce costs and increase efficiency, effective control of risk, realize enterprise transformation and upgrading, and innovative development."
If you want to know more financial news in real time, welcome to follow us.